spacer
home > ebr > spring 2002 > interim management within life science companies
PUBLICATIONS
European Biopharmaceutical Review

Interim Management Within Life Science Companies

Reaching what are often well publicised milestones, or striving to gain or retain a competitive advantage is very much about taking calculated risks, about making decisions where the outcome is less than certain. If there is a successful outcome, the hero is born - if only for a day. If companies do stumble somewhat, then let us applaud the fact that there was courage enough for a decision in the first place. Then let us learn and move forward.

But What if Progress is Hindered Due to Avoidable Causes?

It is people who make decisions, and who subsequently implement them, and in today's tough and unforgiving marketplace, the absence of experienced and competent individuals within an organisation is now rightly deemed to be unacceptable. Indeed, the permanent recruitment of high quality staff is critical and does take time, but not having the right people in the right place - exactly when they are needed - is simply not acceptable anymore.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Geoff Newman, Managing Director of Interea International Ltd

Geoff Newman is the Co-Founder and Managing Director of Interea International, a provider of senior level Interim Management to the UK and international life sciences sector. Geoff graduated with First Class Honours in Chemistry from Durham University, before joining the pharmaceutical industry.
His career has encompassed commercial and general management roles within a number of companies, and has included significant overseas postings in Switzerland, Japan and the US.

spacer
Geoff Newman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>

White Papers

A Rules Based Approach to Labelling and Artwork Management

Kallik

Many organisations today are experiencing unprecedented demands from regulatory authorities and consumers alike for product labelling to be made clearer and more informative. Forthcoming regulations (including the new EU MDR regulations coming into force May 2020) also require that labelling content to be published electronically in addition to print. As companies seek to continuously differentiate themselves in established markets as well as gain entry into new territories, the increase in both volume and complexity of product and market variations will have a direct impact on labelling.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement